CLAIMS:

1. A compound of Formula (I),



Formula (I)

wherein

A represents a direct bond or optionally substituted C_{1-5}alkylene;

$\mathbf{R^1}$ represents hydrogen; optionally substituted C_{1-8}alkyl; or $(CH_2)_b$-$\mathbf{R^a}$, wherein

$\mathbf{R^a}$ represents C_{3-8}cycloalkyl and **b** is zero or an integer from 1 to 6;

$\mathbf{R^2}$ represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, $N\mathbf{R^3R^{3a}}$, optionally substituted C_{1-8}alkyl, optionally substituted C_{1-8}alkoxy or halo;

$\mathbf{R^3}$ and $\mathbf{R^{3a}}$ are independently selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

$\mathbf{R^4}$ is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g** , **III-h**, **III-i**, **III-j** or **III-k**;



wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a}, are selected from:

(i) R^6 and R^{6a} are independently selected from hydrogen and optionally substituted C_{1-8}alkyl; or

(ii) R^6 and R^{6a} together represent carbonyl; or

(iii) R^6—A-N-R^7 represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and R^{6a} represents hydrogen and optionally substituted C_{1-8}alkyl;

R^7 represents hydrogen or optionally substituted C_{1-8}alkyl;

R^8 are selected from: : C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and heterocyclyl wherein R^8 is optionally substituted with halo, hydroxy, amino, NO_2, cyano, C_{1-4}alkanoyloxy, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH-, HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-, -$S(O_n)$-C_{1-4}alkyl, - N(**R**)$S(O_n)$-C_{1-4}alkyl, -$S(O_n)$N(**R**)-C_{1-4}alkyl or heterocyclyl optionally substituted by C_{1-4}alkyl, C_{2-4}alkenyl or C_{2-4}alkynyl, wherein **R** is hydrogen or C_{1-4}alkyl;

R^9 is selected from:

(i) R^9 represents hydrogen, aryl, a 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl; and

(ii) the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

R^{10} meets the definition in option (ii) for R^9 above or when R^9 meets the definition in option (i) above R^{10} represents hydrogen or optionally substituted C_{1-8}alkyl;

R^{12} and R^{12a} are selected from:

(i) R^{12} and R^{12a} are independently selected from hydrogen or optionally substituted C_{1-8}alkyl; or

(ii) R^{12} and R^{12a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R^{13} and R^{14} are selected from:

(i) R^{13} is selected from hydrogen; optionally substituted C_{1-8}alkyl; optionally substituted aryl; $-R^d$-Ar, where R^d represents C_{1-8}alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R^{14} is selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

(ii) wherein R^4 represents a group of formula **III-a , III-b** or **III-i**, then the group $NR^{13}(-R^{14})$ represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

(iii) wherein R^4 represents structure **III-e**,  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

n is 0 to 2;

or a salt, pro-drug or solvate thereof.

2. A compound according to Claim 1 wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl and R^{10} represents hydrogen or optionally substituted

C_{1-8}alkyl wherein the optional substituents on aryl, the heterocyclic ring and C_{1-6}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, -O-$\mathbf{R^b}$, C(O)N$\mathbf{R^bR^c}$, -N$\mathbf{R^bR^c}$, -N$\mathbf{R^c}$C(O)-$\mathbf{R^b}$, -C(O)N$\mathbf{R^bR^c}$, -N$\mathbf{R^c}$S(O_{0-2})$\mathbf{R^b}$, -S(O_{0-2})$\mathbf{R^b}$, wherein $\mathbf{R^b}$ and $\mathbf{R^c}$ are as in Claim 1.

3. A compound according to Claim 2 wherein $\mathbf{R^9}$ is a C_{1-6}alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benztriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetinyl, each of which is optionally substituted.

4. A compound according to Claim 1 wherein the structure N($\mathbf{R^9R^{10}}$) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.

5. A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from $\mathbf{R^{15}}$ wherein $\mathbf{R^{15}}$ is selected from optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4}alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-6}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, -O-$\mathbf{R^b}$, C(O)N$\mathbf{R^bR^c}$, -N$\mathbf{R^bR^c}$, -N$\mathbf{R^c}$C(O)-$\mathbf{R^b}$, -C(O)N$\mathbf{R^bR^c}$, -N$\mathbf{R^c}$S(O_{0-2})$\mathbf{R^b}$, -S(O_{0-2})$\mathbf{R^b}$, wherein $\mathbf{R^b}$ and $\mathbf{R^c}$ are as defined in Claim 1.

6. A compound according to any one of the preceding claims wherein R^4 is selected from a group of formula **III-a , III-g, III-h, III-i, III-j or III-k**:



III-a



III-g



III-h



III-i



III-j



III-k

6. A compound according to any one of the preceding claims wherein **X** and R^8 represent either:-

(a) **X** represents N and R^8 represents cyano or –C(O)O-R^b; or

(b) **X** represents N and R^8 represents hydrogen.

7. A compound according to any one of the preceding claims wherein R^2 is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^eR^f, optionally substituted C_{1-8}alkyl, optionally substituted C_{1-8}alkoxy or halo wherein R^e and R^f are independently selected from hydrogen, C_{1-6}alkyl or aryl.

8. A compound according to any one of the preceding claims wherein R^1 is hydrogen.

9. A compound selected from:

isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate;

isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate; and

2-[({[(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]amino}carbonyl)oxy]-2-methylpropyl acetate

or a salt, pro-drug or solvate thereof.

10. A compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 9 for use as a medicament.

11. A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 9 and a pharmaceutically acceptable diluent or carrier.

12. Use of a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 9, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.

13. A process of producing a compound, or salt, pro-drug or solvate thereof, according to Claim 1, wherein the process comprises a reaction step selected from any one of steps (a) to (b):-

(a) Reaction of a compound of formula **XXXII** as follows



XXXII **XXXIII**

where **X** is a leaving group;

(b) Reaction of a compound of Formula XXXIV as follows



XXXIV XXXV

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.